Home » News » Urology » Upper tract urothelial carcinoma
Upper Tract Urothelial Carcinoma
UPPER TRACT UROTHELIAL CARCINOMA
Genomic screening for Lynch syndrome, hereditary breast and ovarian cancer syndrome, and familial hypercholesterolemia likely cost-effective for adults younger than 40 years
The new guideline aims to limit toxicity and improve cancer control and survival in patients with UTUC.
Findings are based on a study of 215 patients who underwent 392 endoscopic procedures for upper tract urothelial carcinoma.
Findings of a phase 2 trial support the use of neoadjuvant chemotherapy as a standard of care, according to investigators.
Receipt of neoadjuvant vs adjuvant chemotherapy did not differ significantly by clinical nodal stage.
For patients with low-grade residual disease, complete response rate was 70% with UGN-101
An accurate estimate of future GFR after nephrectomy would help to guide operative strategy and use of adjuvant or neoadjuvant therapies, according to a recent editorial.
Adjuvant chemotherapy prolongs survival among patients with negative surgical margins regardless of number of positive lymph nodes.
Findings may inform surveillance strategies and improve treatment outcomes.
Approximately one-quarter of patients aged 80 years or older with upper tract urothelial carcinoma are managed expectantly, data show.
Load More
Open
Next post in Upper tract urothelial carcinoma
Close
Close more info about Neoadjuvant Chemotherapy Beneficial in High-Risk UTUC
Loading...
Close more info about Neoadjuvant Chemotherapy Beneficial in High-Risk UTUC
Loading...